News | Myriad Genetics

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Apr 30, 2025 | Products

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Apr 29, 2025 | Corporate | Financial

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 25, 2025 | Products

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 21, 2025 | Products

Myriad Genetics Announces Inducement Awards

Apr 08, 2025 | Corporate | Financial

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Apr 07, 2025 | Corporate

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Feb 27, 2025 | Products

Myriad Genetics Announces Senior Leadership Transition

Feb 24, 2025 | Corporate | Financial

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Feb 24, 2025 | Corporate | Financial

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Feb 24, 2025 | Corporate | Pipeline | Products

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Feb 19, 2025 | Corporate

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Feb 18, 2025 | Corporate | Financial

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Feb 06, 2025 | Products

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Feb 05, 2025 | Corporate | Pipeline

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Feb 05, 2025 | Products

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Jan 29, 2025 | Products

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Jan 23, 2025 | Products

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Jan 21, 2025 | Products | Corporate

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Jan 15, 2025 | Financial | Corporate

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Jan 09, 2025 | Products | Corporate

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 08, 2025 | Corporate | Financial

NASDAQ:

MYGN

$7.41

2.92%

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

04/30/2025

NASDAQ:

MYGN

$7.41

2.92%

News Releases

Select year

Categories

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Myriad Genetics Announces Inducement Awards

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Myriad Genetics Announces Senior Leadership Transition

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report